Clinical Trials Logo

Clinical Trial Summary

The vital signs are critical in assessing the severity and prognosis of infections, such as Covid-19. The devices used today for measuring the vital signs have to be in physical contact with the patients. There is an apparent risk of transferring infections from one patient to the next (or to healthcare professionals). This project aims to evaluate a new camera-based system for contactless measurement of vital signs as well as an artificial intelligence (AI) predicting hospitalization or death within 30 days. This particular study will evaluate the new system's ability without interfering with standard care of the patient.


Clinical Trial Description

Background and aim: The vital signs are critical in assessing the severity and prognosis of infections, i.e., Covid-19, influenza, sepsis and pneumonia. Quick and accurate triage is critical when facing a pandemic with an overwhelming number of cases (confirmed and suspected). This study aims a) to evaluate a new method for rapid camera-based non-contact measurement of five vital signs; body temperature, heart rate, blood oxygen saturation, respiratory rate, and blood pressure, and b) if an AI can predict hospitalization or death within 30 days. Methods: A method-comparison study design is used comparing each vital sign measured with the new method to the corresponding standard reference method. Furthermore, a cohort design is used to follow up any hospitalization or death within 30 days. The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face. First, all vital signs will be measured using one set of reference devices. Secondly the investigated device will record a 30 second video of the patient's face. Thirdly, and last, all vital signs will be measured using the same set of reference devices. A copy of the vital sign readings (using the standard reference methods) will be handed over by an investigator to the clinical professionals responsible for the subsequent medical care for each subject. Afterwards, the collected 30-second recordings will be run through specific software algorithms to extract the vital signs. The results from the new camera-based contactless measurement of vital signs and the outcome of the AIs prediction of risk for hospitalization or death will not be presented in the care situation of the patient. Expected Findings: It is expected that the proposed study will show that the new method can estimate body temperature, heart rate, respiratory rate, blood oxygen level, and blood pressure with an acceptable agreement compared with the reference method and also estimate hospitalization or death within 30 days. Implications of the expected findings: Being able to measure vital signs quicker than before by using a new contactless method would greatly facilitate triage of large number of patients. Also being able to predict hospitalization or increased risk for death would further improve the triage of patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04383457
Study type Observational [Patient Registry]
Source Vastra Gotaland Region
Contact
Status Completed
Phase
Start date June 15, 2020
Completion date October 8, 2020

See also
  Status Clinical Trial Phase
Completed NCT04553575 - CoViD-19 Patient in Reims University Hospital in March to April 2020
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Active, not recruiting NCT05548439 - Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a Phase 1
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Active, not recruiting NCT05726084 - Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older Phase 2/Phase 3
Recruiting NCT05069129 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 1/Phase 2
Enrolling by invitation NCT05054075 - Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Phase 2
Recruiting NCT05599516 - Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial Phase 3
Completed NCT05047900 - The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community N/A
Completed NCT04420286 - Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
Completed NCT04424355 - Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Enrolling by invitation NCT04327349 - Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial N/A
Completed NCT04321278 - Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Phase 3
Recruiting NCT04327570 - In-depth Immunological Investigation of COVID-19.
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Recruiting NCT04322344 - Escin in Patients With Covid-19 Infection Phase 2/Phase 3
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A
Completed NCT04323592 - Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome